In this special edition episode, hosts break down what the announcement of the 10 drugs selected for Medicare price negotiations under the Inflation Reduction Act means for providers and people with diabetes.
The three largest insulin manufacturers in the United States have all announced they will cap out-of-pocket costs of their popular insulin products at $35 per month, following political pressure from Congress.